MOSCOW (Reuters) – Russia will begin Phase III trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Friday.
Early-stage clinical trials for the vaccine were completed on Wednesday.
(Writing by Alexander Marrow; Editing by Polina Ivanova)
